H.C. Wainwright analyst Edward White maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price target of $32. The company’s shares closed on Wednesday at $8.90.
“We find the label compelling and inline with expectations. Commercial launch for Xpovio expected next week. Karyopharm has developed a strategic plan going forward in order to ensure a successful launch of Xpovio, which management believes gives support to future launches in other indications as well. The company hired over 70 employees, with an average of about 20 years pharmaceutical experience and approximately five years of MM experience, in sales and nursing liaison positions in January 2019. The sales team plans on educating professionals and patients regarding how to effectively administer the drug and guiding them through the drug’s side effect profile. Karyopharm is working with payors and is attempting to minimize access barriers for appropriate patients as well as helping them stay on treatment.”
According to TipRanks.com, White is a 5-star analyst with an average return of 21.9% and a 52.8% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Aeglea Biotherapeutics Inc, and Spectrum Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Karyopharm Therapeutics with a $29 average price target.
The company has a one-year high of $21.71 and a one-year low of $3.92. Currently, Karyopharm Therapeutics has an average volume of 1.24M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company. It is engaged in the discovery, development, and commercialization of drugs to treat cancer and other major diseases.